Cargando…
Does health technology assessment compromise access to pharmaceuticals?
In response to rapidly rising pharmaceutical costs, many countries have introduced health technology assessment (HTA) as a ‘fourth hurdle’. We evaluated the causal effect of HTA based regulation on access to pharmaceuticals by using the introduction of Germany’s HTA system (AMNOG) in 2011. We obtain...
Autores principales: | Büssgen, Melanie, Stargardt, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060338/ https://www.ncbi.nlm.nih.gov/pubmed/35708786 http://dx.doi.org/10.1007/s10198-022-01484-4 |
Ejemplares similares
-
Does health technology assessment compromise access to pharmaceuticals?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades
por: Büssgen, Melanie, et al.
Publicado: (2022) -
Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
por: Drummond, Michael, et al.
Publicado: (2010) -
Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany: Methodologies and criteria
por: Busse, Reinhard, et al.
Publicado: (2005)